more

Novartis (NVS)

(Real Time Quote from BATS)

$113.78 USD

-0.08 (-0.07%)

Updated Oct 8, 2024 12:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate

by Zacks Equity Research Published on August 13,2019

Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.

pharmaceuticals

Here's Why Amgen Stock is Outperforming Its Industry Of Late

by Zacks Equity Research Published on August 13,2019

Favorable patent ruling related to Enbrel and strong second-quarter results drive Amgen (AMGN) stock 22.6% higher in the past three months.

biotechs

Amgen Wins Enbrel U.S. Patent Litigation Against Novartis

by Zacks Equity Research Published on August 12,2019

Despite lower demand hurting volumes of Enbrel, it remains the largest drug for Amgen (AMGN). A district court decision prevents Novartis from launching Erelzi, its biosimilar version of Enbrel.

biotechs

Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2

by Zacks Equity Research Published on August 09,2019

Intrexon (XON) posts a narrower-than-expected loss and misses sales estimates in the second quarter of 2019.

pharmaceuticals

Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research Published on August 09,2019

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports second-quarter 2019 results.

Has Novartis (NVS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research Published on August 09,2019

Is (NVS) Outperforming Other Medical Stocks This Year?

NVSNegative Net Change

NVS vs. NVO: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research Published on August 08,2019

NVS vs. NVO: Which Stock Is the Better Value Option?

2 Marijuana Stocks to Buy Heading into Q2 Earnings and Beyond

by Mitchell Moore Published on August 07,2019

The marijuana industry is projected to grow at an annual rate of about 17% until it reaches $55.8 billion a year in 2025. The cannabis market has roughly tracked the S&P 500' s expansion in 2019 so far.

Mallinckrodt (MNK) Q2 Earnings Beat, Generics Spin-off on Hold

by Zacks Equity Research Published on August 07,2019

Mallinckrodt (MNK) beats on earnings in Q2 but marginally misses on revenues. The company suspends plan to spin-off the generic business for now.

pharmaceuticals

Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies

by Zacks Equity Research Published on August 07,2019

Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.

Aduro (ADRO) Earnings Miss in Q2, Revenues Meet Estimates

by Zacks Equity Research Published on August 05,2019

Aduro (ADRO) suffers wider-than-expected loss in the second quarter while revenues match estimates.

Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger

by Kinjel Shah Published on August 02,2019

AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.

pharmaceuticals

United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Down Y/Y

by Zacks Equity Research Published on August 01,2019

United Therapeutics (UTHR) beats estimates on both fronts in the second quarter. Loss of exclusivity for Adcirca and lower sales of Remodulin hurts sales.

pharmaceuticals

Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat

by Zacks Equity Research Published on July 31,2019

Ligand (LGND) reports better-than-expected second-quarter 2019 results and maintains view for the full year.

Gilead (GILD) Q2 Earnings & Sales Beat, Sales Guidance Raised

by Zacks Equity Research Published on July 31,2019

Gilead (GILD) beats on Q2 earnings and sales on solid performance of the HIV franchise. The company also raises its sales guidance for the year.

biotechs